Q91365 AF NFT

Centrosomal protein of 162 kDa (Fragment)

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeihbzj7qwz4jcfsn4hnnar5ccuz6jwqa6m2zwslgixbojyrjxfd6q4/metadata.json
IPFS of structure file: 
bafybeia5m7t7dq56bpoyei2nh6hfsjwsl6udqldwpwxw6y447zmmkaxfw4/AF-Q91365-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x9e5E98E011361C5888c92e2CDb7652E02Bd5C7Ed
First NFT owner address (bech32): 
genesis1ne0f3cq3xcw93zxf9ckdkajjuq4at3ldwq49kv
Current NFT ID #57639 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
57639
Accession (UniProt):
Q91365
Name::
Centrosomal protein of 162 kDa (Fragment)
Experimental Method:
Predicted structure
Sequence source:
COTURNIX COTURNIX

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT Q91365 research and analysis (ICN3D with VR)

FASTA sequences

>sp|Q91365|CE162_COTCO Centrosomal protein of 162 kDa (Fragment) OS=Coturnix coturnix OX=9091 GN=CEP162 PE=1 SV=1 MLEKFHKNKKDSYLNKEEGSLTSDGSDSPKEILETSERIVKKALQLTEETDENVHPEKMQLQKSNGVAFSLSRDSLETNDSFVASGPNQSNTGLGLDTLEEQEEKEIFFAKLEQEASSPIDYSRLNKELNLSDSIVLAPFVRNESEKEVESTAEEKCESYSEDFEEDTDANPAFKTEESQEPNSGMLAKVVLLDSQDSTTEFQKAAETSGVALSEHDLPQEVGGTEMNEAGTLCGQTTSDTEALHHAYHHHIDQSLGDTDEQKIHSSSMAISQCLVQVTSQNHNLYSKNTSTTESDLPTVEEFMRPIKGDCYNARGFDLEPESPVKVIGSTVNEHVNHLPYKEHKNESVWETNLLEKFNREDSIFLQTAANEDSFLRMPGKEIQTSEVQPDVLSKEIIQDCLLSQGSKTKQVLQSCCLKNEKSESTTTKQMLYKNIRSTTPLHKKKSSYGPHGVVRSSGYGKSTSYSKQSIPATERKIPKETLKKSIMKCRSPADKARSKEALFTTRTIRSAANQQASKEDISRAMPDQSVVQNLGHQVVDSFRQHHSDLPVSPVKSCERELRLLRRAQVAEEDLSRARDVIQQLTSTVSEKEKEMETKIVELKTRYEKELSQLGQENYVLQSKLRSVEELSKEKRWIHQTGTVSVPEEKLAQIQKEMEDQEVIIQGYQQENERLYKQMKDLQIQNKKNEEQMYKENQCLMSELIALREKVERINIQSQIVRESEPARNQSFTELISELRAARKEETKLREEIRRLKQDKQALELDLGQAKKERDLAKVQITSTSSEKSYEFKIMEETYKQEILHLKRRLHWYAENQDLLDKDAARLKEAREEIEKLKQEVKKLRAEAGDHQCVQQKKRLRDRAADAKRIQDLERQIKEMEGILKRRYPNSLPALIYAAAAAEKTNDLSAKTNTTDFLERRIKKLETELEGKDDEAKTSLRAMEQQFQKIKMQYEQRLAELEQLLAYKWKSESPKLNGDKANCIELELQLQNLKKTHQITVENLQTEIENLKSQNSQLKLRSKKDNKDLQLADWQMKQGNTKEKLLKLNQELITKNREIQDLTKTVEKLQKERMAMLSDNNLRNKTDNKENRQESLKNNTVATEKRNSCNSEPLIGIFNNDKIYQPHNFSDSNVLEVLQENARLKEEVEKLSLEMNQQRVKSQATLAYSENNIRRIQEDTAEYVAALKASHQREVEKILSQYTKDDSASKVAELNGRISTQEILIKHLQEQISEHQRHQEALLVSQMREEF